German study recommends UBC® Rapid to be added in the diagnostics and follow-up of high risk bladder cancer | IDL Biotech
IDL Biotech

CLOSE MENU

Articles

Latest News

December 2018

German study recommends UBC® Rapid to be added in the diagnostics and follow-up of high risk bladder cancer

International Journal of Molecular Sciences has published a study on UBC® Rapid. In total 530 urine samples was included in the multicenterstudy.

The author of the study concluded that elevated values of UBC® Rapid Test in urine are higher in patients with non-muscle invasive high-grade bladder cancer in comparison to low-grade tumors and the healthy control group. Sensitivity for non-muscle invasive high-grade tumors is very high with 75% at a specificity of 93.8%. Thus, UBC® Rapid Test has the potential to be a more sensitive and specific urinary protein biomarker to identify patients with high-grade tumors that are difficult to detect in cystoscopy.

 

Results for UBC® RapidTest in both study centers of the present multicenter study are very similar and reproducible. UBC® Rapid Test is standardized and calibrated, and thus independent of use, batch of test, as well as study site.  UBC® Rapid Test should be added in the diagnostics and follow-up for NMI-HG tumors of urinary bladder cancer, though cystoscopy is still an important part of monitoring of bladder cancer.

Interview with Charlotte Berg

On Saturday the 17th of November, the Swedish newspaper SvD, had an interview with the CEO, Charlotte Berg.

IDL Biotech AB offentliggör prospekt för beslutad företrädesemission

Styrelsen i IDL Biotech AB (Publ) har upprättat ett prospekt med anledning av den förestående nyemissionen med företrädesrätt för IDL Biotechs aktieägare. Prospektet har idag godkänts och registrerats av Finansinspektionen.

IDL Biotech

Skip this intro